StreetInsider.com News Articles http://162.242.133.50 Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Sep 2025 10:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://162.242.133.50 143 28 0 1 2 3 21 22 23 Saturday Sunday Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/Press+Releases/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Equity Litigation Group LLP Announces Pendency and Proposed Settlement of Stockholder Class Action for All Record Holders and Beneficial Holders of Shares of NGM Biopharmaceuticals, Inc., Common Stock http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Sept. 8, 2025</chron></span> /PRNewswire/ -- </p> <p>IN THE COURT OF CHANCERY OF THE <location value="LS/us.de" idsrc="xmltag.org" >STATE OF DELAWARE</location></p> <p>CHARLES BRYANT,                                                            </p> <p>                                      Plaintiff,                      </p> <p>                   v.                                             C.A. No.: 2024-1314-MTZ            </p> <p>THE COLUMN GROUP, LP,           <br/><person>DAVID V. GOEDDEL</person>, and                        <br/>DAVID J. WOODHOUSE,                                                                        </p> <p>                                      Defendants.</p> <p class="prntac"><b>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING, AND <u>RIGHT TO APPEAR</u></b></p> <p><b>TO:   </b>All record holders and http://www.streetinsider.com/PRNewswire/Equity+Litigation+Group+LLP+Announces+Pendency+and+Proposed+Settlement+of+Stockholder+Class+Action+for+All+Record+Holders+and+Beneficial+Holders+of+Shares+of+NGM+Biopharmaceuticals%2C+Inc.%2C+Common+Stock/25307163.html Mon, 08 Sep 2025 10:00:00 -0400 A.23617704 NGM O.00041625 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Press+Releases/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html <p class="bwalignc"> <i>Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development</i> </p><p class="bwalignc"> <i>Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxaira.com%2F&amp;esheet=54287516&amp;newsitemid=20250709514365&amp;lan=en-US&amp;anchor=Xaira+Therapeutics&amp;index=1&amp;md5=92fdc0e222d825329e0aa256e37b40c7" shape="rect">Xaira Therapeutics</a> today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira http://www.streetinsider.com/Business+Wire/Xaira+Therapeutics+Announces+the+Appointment+of+Jeff+Jonker+as+President+and+Chief+Operating+Officer/25032806.html Wed, 09 Jul 2025 12:00:00 -0400 A.19465411 A.22194166 A.40151759 NGM O.00050368 O.00053334 O.22422653 Form 15-12G NGM BIOPHARMACEUTICALS http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23064869.html si-local-file:///var/storage/secattach/20240415/23064869.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23064869.html Mon, 15 Apr 2024 07:58:00 -0400 NGM O.06072529 Form 15-12G NGM BIOPHARMACEUTICALS http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23064869.html si-local-file:///var/storage/secattach/20240415/23064869.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23064869.html Mon, 15 Apr 2024 07:58:00 -0400 NGM O.06072529 Form EFFECT NGM BIOPHARMACEUTICALS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23042882.html si-local-file:///var/storage/secattach/20240409/23042882.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23042882.html Tue, 09 Apr 2024 06:03:00 -0400 NGM O.06072529 Form EFFECT NGM BIOPHARMACEUTICALS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23042882.html si-local-file:///var/storage/secattach/20240409/23042882.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NGM+BIOPHARMACEUTICALS+++++++++++++++/23042882.html Tue, 09 Apr 2024 06:03:00 -0400 NGM O.06072529 Form 4 NGM BIOPHARMACEUTICALS For: Apr 05 Filed by: TCG Opportunity III GP, LLC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NGM+BIOPHARMACEUTICALS++++For%3A+Apr+05++Filed+by%3A+TCG+Opportunity+III+GP%2C+LLC/23041989.html si-local-file:///var/storage/secattach/20240408/23041989.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NGM+BIOPHARMACEUTICALS++++For%3A+Apr+05++Filed+by%3A+TCG+Opportunity+III+GP%2C+LLC/23041989.html Mon, 08 Apr 2024 20:06:00 -0400 NGM O.06072529